Celcuity CELC
NASDAQ CELC
$94.63 -1.81 (-1.87%)
As of: Sep 4, 2026 · 12:52 PM EDT

Celcuity (CELC) Income from Non-Controlling Interests (2020 - 2021)

Celcuity's (CELC) quarterly Income from Non-Controlling Interests came in at $21.0 in Q2 2021, down 32.26% YoY from $31.0 in Q2 2020, and down 12.5% on a QoQ basis from $24.0 in Q1 2021.

Analysis

Celcuity (CELC) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends

Celcuity (CELC) has 2 years of Income from Non-Controlling Interests data on file, last reported at $21.0 in Q2 2021.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Inc. Minority (Qtr)
1 Vertex Pharmaceuticals 139.62 Bn 131.77 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.73 Bn 77.73 Bn 3.93 Bn -
3 Argenx Se 63.53 Bn 58.35 Bn 1.37 Bn -
4 Moderna 58.23 Bn 53.09 Bn 52.00 Mn -
5 Revolution Medicines 44.05 Bn 44.05 Bn - -
6 BeOne Medicines 40.03 Bn 34.93 Bn 1.53 Bn -
7 Alnylam Pharmaceuticals 35.50 Bn 32.19 Bn 992.69 Mn -
8 Royalty Pharma 28.52 Bn 27.68 Bn - 63.60 Mn
9 Insmed 27.46 Bn 26.30 Bn 358.27 Mn -
10 Celcuity 5.19 Bn 5.19 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2021 21.00
Mar 31, 2021 24.00
Sep 30, 2020 28.00
Jun 30, 2020 31.00